በህንድ ዋና ከተሞች የአጥንት መቅኒ ንቅለ ተከላ ዋጋ – ዴሊ፣ ሙምባይ፣ ቼናይ፣ ባንጋሎር እና ሃይደራባድ

At NABH/JCI-accredited Divinheal partner hospitals, an autologous BMT usually costs about ₹8,00,000–₹20,00,000 (≈ $8,440–$21,080; AUD 11,700–29,245; £6,215–£15,535). A matched-donor allogeneic BMT is generally ₹20,00,000–₹40,00,000 (≈ $21,080–$42,155; AUD 29,245–58,500; £15,535–£31,065), while a haploidentical transplant using a half-matched family donor is typically ₹25,00,000–₹45,00,000 (≈ $26,347–$47,425; AUD 36,555–65,800; £19,420–£34,950). These figures mainly cover the procedure and hospital stay, with post-transplant medicines and longer accommodation added separately.

Autologous is the least expensive — using your own cells removes donor-related costs and usually means a shorter hospital stay. Allogeneic costs more for several reasons. You need donor HLA matching. International registry search fees apply for unrelated donors. Stronger immune-suppressing drugs are needed. And the hospital stay averages 4–6 weeks. Haplocord is the most complex and most expensive type. It needs the most intensive GVHD prevention. But it opens access for patients without a fully matched donor.

BMT costs mainly vary based on a few key factors—the type of transplant (autologous, allogeneic, or haploidentical), how advanced the disease is, and the donor source. If a donor registry search is needed, it can add around $3,000–$10,000. The hospital you choose also matters, along with any complications like infections or GVHD and how long you stay admitted. After discharge, you should also plan for nearby accommodation and monthly immunosuppressive medicines, which usually cost about ₹20,000–₹80,000 in the first year. Divinheal shares a clear written estimate before you make any commitment.

No. Medicare (Australia) does not cover medical treatment done overseas, including BMT in India. NHS UK coverage only applies to UK residents receiving treatment within the NHS. Some private Australian or UK health insurance policies may partly cover overseas BMT. This applies if the policy includes international surgical or specialist benefits. Check your specific policy for overseas treatment and pre-existing condition clauses. Most standard private health policies do not cover overseas BMT. Divinheal can provide itemised cost documentation from NABH-accredited partner hospitals for patients who wish to submit insurance claims.

Published CIBMTR and EBMT data: AML in first remission: 50–65% 5-year overall survival after matched allogeneic BMT. ALL in first remission: 50–60%. Aplastic anaemia: 80–90% long-term survival after matched sibling allogeneic BMT. Thalassaemia major: 85–95% 5-year survival in paediatric patients after matched sibling BMT. Multiple myeloma: median progression-free survival 2–4 years after autologous BMT with modern maintenance. These are population-level estimates; individual prognosis depends on disease stage, age, performance status, and HLA match quality. Consult your haematologist for a personalised prognosis.

Yes — BMT is a high-risk procedure. Key risks include: GvHD (acute: 30–50% of allogeneic recipients; chronic: 30–60% of long-term survivors); serious infections during the low white cell count phase; primary graft failure (2–5%); organ toxicity from conditioning; and relapse. Risk is much lower at high-volume, NABH/JCI-accredited centres with full BMT teams including blood cancer doctors, infection specialists, and critical care physicians. All Divinheal partner hospitals have these capabilities.

For patients from Australia and the UK who cannot get public BMT through the NHS or Medicare, India offers the strongest mix of clinical quality and affordability. JCI-accredited BMT centres in India use the same setup as UK and Australian BMT units — HEPA isolation, molecular HLA typing, and apheresis. Yet they cost 70–85% less. European countries (Germany, Spain, Turkey) are also established BMT destinations, but cost more than India. The USA has excellent BMT centres but very high costs for international patients ($200,000–$500,000 for allogeneic BMT).

For the conditions where BMT is indicated — especially AML, ALL, aplastic anaemia, and thalassaemia — it is often the only potentially curative treatment. The decision means weighing the serious risks of the procedure against the risks of the underlying disease without a transplant. For many patients, BMT offers the best or only realistic path to long-term survival or cure. Your blood cancer doctor is the right person to assess whether BMT is right for your specific disease, stage, and overall health.

Yes. Long-term survival of 20 years or more after BMT is well-documented. This is especially true for patients with aplastic anaemia, thalassaemia, or leukaemia transplanted in early remission. Patients who are disease-free at 5 years have much better prospects for long-term survival. Late effects — secondary cancers, chronic GvHD, cardiovascular risk, osteoporosis — require ongoing medical check-ups. But they do not stop most survivors from living long, active lives.

Salman Khan has publicly stated that he is registered as a bone marrow donor and has encouraged bone marrow donation. He has been an active advocate for the Being Human Foundation and has spoken about bone marrow donation at public events. He has not confirmed completing an active donation. Bone marrow donation in India is regulated and voluntary. Registering as a potential donor is free and non-invasive. You give a cheek swab or blood sample through registries, including the DATRI Blood Stem Cell Donors Registry. A registered donor is only called upon if they are a match for a specific patient requiring a transplant.

Human bone marrow is not commercially traded — buying or selling human tissue is illegal under Indian law and the laws of most countries. Bone marrow donation is entirely voluntary, and donors receive no payment in India under the regulatory framework. The costs associated with BMT (procedure, hospital stay, medication, donor search and coordination) do not reflect a ‘price’ for the bone marrow itself. They reflect the medical services needed to collect, process, and transplant it safely. Unrelated donor search fees ($3,000–$10,000) cover registry admin, HLA typing, donor medical evaluation, and stem cell collection logistics. They are not a payment to the donor.

Divinheal’s top partner hospitals for BMT are listed below. • Medanta Gurgaon (JCI, NABH) — dedicated BMT unit with HEPA isolation and haploidentical programme • Apollo Hospitals Chennai (JCI, NABH) — high-volume blood cancer care with strong international patient support • MAX Hospitals (NABH) — full BMT programme for leukaemia, lymphoma, and myeloma • Artemis Gurgaon (JCI, NABH) — integrated oncology and BMT pathway • Fortis Noida (NABH) and Paras Hospitals (NABH) — cost-accessible NABH-accredited BMT Divinheal matches patients to the right partner hospital based on BMT type, disease, and budget.

Divinheal provides all of the following. A named BMT doctor reviews your case before travel. You receive a written treatment plan and cost estimate in AUD or GBP before you commit. Divinheal provides the Indian Medical Visa invitation letter. They arrange accommodation near the hospital for the transplant and recovery period. Airport transfers and a WhatsApp-accessible patient coordinator are included. After you return home, Divinheal arranges a telemedicine follow-up with the India BMT specialist. A written discharge summary goes to your Australian or UK blood cancer doctor. There is no placement fee. All partner hospital rates are direct patient pricing.

Hospital stay: 3–6 weeks for autologous BMT; 4–6 weeks for allogeneic BMT; 5–7 weeks for haploidentical. After hospital discharge, most blood cancer doctors recommend staying near the transplant centre for 8–12 additional weeks before returning home. Full immune recovery takes 6–12 months. Full return to normal activity for most patients occurs 6–24 months post-transplant. This depends on disease type, transplant type, and whether complications such as chronic GvHD occur.